ReShape Lifesciences Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
HIND$1.59+0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · · 2023 · 2022 | ||||||
| Net loss | | $(11,387) | | $(46,214) | ||
| Foreign currency translation adjustments | | | — | | | 4 |
| Other comprehensive income, net of tax | | | — | | | 4 |
| Comprehensive loss | | $(11,387) | | $(46,210) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.